On January 14, 2026, Wuxi Apptec (603259.SH, 02359) delivered a keynote speech at the 44th annual J.P. Morgan Healthcare Conference, providing an update on its business progress. According to the disclosed data, as of the third quarter of 2025, the company's total small-molecule CDMO pipeline reached 3,430 projects, accounting for 16% of the global new drug pipeline in clinical stages; within this, Phase III and commercialized projects have reached 167.

The company reviewed the number of Phase III and commercialized projects and their corresponding revenue generated in recent years. Since 2022, the number of molecules in Phase III and commercialization has grown from 107 to 167, a significant increase of 56%. Corresponding revenue surged from 4.7 billion yuan to 10.3 billion yuan in 2024, with this year's figures expected to reach a new high.

Recently, oral drugs, leveraging their significant advantage of convenient administration, are rapidly replacing injectables across major global therapeutic areas, emerging as a new focal point in the pharmaceutical industry. Just recently, the industry media Endpoints News listed "Pills" as one of the keywords for 2025, highlighting the strong rise of this segment—from lipid-lowering drugs and psoriasis treatments to next-generation weight-loss medications, oral formulations are continuously expanding into areas like obesity, heart disease, and inflammatory diseases, steadily capturing market share previously dominated by large-molecule biologics.